Vertex Pharmaceuticals Announces Acquisition of Crinetics Pharmaceuticals and Reports Q2 2026 Results

Details

The company raised its full-year revenue guidance to $13.1 to $13.2 billion. Vertex also announced the acquisition of Crinetics Pharmaceuticals for $10 billion, which is expected to close in the third quarter of 2026. The company highlighted progress in its cystic fibrosis, sickle cell disease, and acute pain therapies, with notable growth in CASGEVY and JOURNAVX revenues.

Items reported

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.